Substrate reduction therapy in juvenile GM2 gangliosidosis

Gustavo H B Maegawa, Brenda L. Banwell, Susan Blaser, Geoffrey Sorge, Maggie Toplak, Cameron Ackerley, Cynthia Hawkins, Jason Hayes, Joe T R Clarke

Research output: Contribution to journalArticle

Abstract

Substrate reduction therapy (SRT) is considered to be a potential therapeutic option for juvenile GM2 gangliosidosis (jGM2g). We evaluated the efficacy of SRT in jGM2g, assessing neurological, neuropsychological and brain magnetic resonance imaging (MRI) outcomes over a 24-month period of treatment. In an open-label and single-center study, five jGM2g patients (mean age 14.6 ± 4.5 years) received oral miglustat at doses of 100-200 mg t.i.d. adjusted to body surface area. Patients underwent general and neurological examinations, neuropsychological, electrophysiological, and brain MRI studies. All patients showed neurological deterioration over the period of the study, with particularly notable worsening of gait, speech and coordination. One patient experienced acute psychosis, and another showed worsening of pre-existing epilepsy. Some neuropsychological tests showed no evidence of deterioration in the three patients with high enough cognitive functioning for reliable assessment. Profound cognitive impairment in two children precluded neuropsychological evaluation. In four patients, evaluation of brain MRI showed no changes in white matter signal abnormalities and cerebellar atrophy noted at baseline, while one patient showed progression of cerebellar and supratentorial brain atrophy. Transmission electron microscopy analysis of peripheral mononuclear cells showed reduction of intracytoplasmatic inclusions with treatment. SRT with miglustat of patients with jGM2g failed to ameliorate progressive neurological deterioration, but apparently no worsening of some areas of cognitive function tested and brain MRI lesions was noted over 24 months of treatment. The results must be interpreted with care owing to the small sample of patients and the lack of a control-arm.

Original languageEnglish (US)
Pages (from-to)215-224
Number of pages10
JournalMolecular Genetics and Metabolism
Volume98
Issue number1-2
DOIs
StatePublished - Oct 2009
Externally publishedYes

Fingerprint

GM2 Gangliosidosis
Magnetic resonance
Brain
Substrates
Deterioration
Imaging techniques
Magnetic Resonance Imaging
Therapeutics
Atrophy
Labels
Transmission electron microscopy
Neuropsychological Tests
Body Surface Area
Neurologic Examination
Transmission Electron Microscopy
Gait
Psychotic Disorders
Cognition
Epilepsy

Keywords

  • Juvenile GM2 gangliosidosis
  • Miglustat
  • Sandhoff disease
  • Substrate reduction therapy
  • Tay-Sachs disease

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Genetics
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Maegawa, G. H. B., Banwell, B. L., Blaser, S., Sorge, G., Toplak, M., Ackerley, C., ... Clarke, J. T. R. (2009). Substrate reduction therapy in juvenile GM2 gangliosidosis. Molecular Genetics and Metabolism, 98(1-2), 215-224. https://doi.org/10.1016/j.ymgme.2009.06.005

Substrate reduction therapy in juvenile GM2 gangliosidosis. / Maegawa, Gustavo H B; Banwell, Brenda L.; Blaser, Susan; Sorge, Geoffrey; Toplak, Maggie; Ackerley, Cameron; Hawkins, Cynthia; Hayes, Jason; Clarke, Joe T R.

In: Molecular Genetics and Metabolism, Vol. 98, No. 1-2, 10.2009, p. 215-224.

Research output: Contribution to journalArticle

Maegawa, GHB, Banwell, BL, Blaser, S, Sorge, G, Toplak, M, Ackerley, C, Hawkins, C, Hayes, J & Clarke, JTR 2009, 'Substrate reduction therapy in juvenile GM2 gangliosidosis', Molecular Genetics and Metabolism, vol. 98, no. 1-2, pp. 215-224. https://doi.org/10.1016/j.ymgme.2009.06.005
Maegawa GHB, Banwell BL, Blaser S, Sorge G, Toplak M, Ackerley C et al. Substrate reduction therapy in juvenile GM2 gangliosidosis. Molecular Genetics and Metabolism. 2009 Oct;98(1-2):215-224. https://doi.org/10.1016/j.ymgme.2009.06.005
Maegawa, Gustavo H B ; Banwell, Brenda L. ; Blaser, Susan ; Sorge, Geoffrey ; Toplak, Maggie ; Ackerley, Cameron ; Hawkins, Cynthia ; Hayes, Jason ; Clarke, Joe T R. / Substrate reduction therapy in juvenile GM2 gangliosidosis. In: Molecular Genetics and Metabolism. 2009 ; Vol. 98, No. 1-2. pp. 215-224.
@article{aa4725d680e141eaabc5507b9e87bf08,
title = "Substrate reduction therapy in juvenile GM2 gangliosidosis",
abstract = "Substrate reduction therapy (SRT) is considered to be a potential therapeutic option for juvenile GM2 gangliosidosis (jGM2g). We evaluated the efficacy of SRT in jGM2g, assessing neurological, neuropsychological and brain magnetic resonance imaging (MRI) outcomes over a 24-month period of treatment. In an open-label and single-center study, five jGM2g patients (mean age 14.6 ± 4.5 years) received oral miglustat at doses of 100-200 mg t.i.d. adjusted to body surface area. Patients underwent general and neurological examinations, neuropsychological, electrophysiological, and brain MRI studies. All patients showed neurological deterioration over the period of the study, with particularly notable worsening of gait, speech and coordination. One patient experienced acute psychosis, and another showed worsening of pre-existing epilepsy. Some neuropsychological tests showed no evidence of deterioration in the three patients with high enough cognitive functioning for reliable assessment. Profound cognitive impairment in two children precluded neuropsychological evaluation. In four patients, evaluation of brain MRI showed no changes in white matter signal abnormalities and cerebellar atrophy noted at baseline, while one patient showed progression of cerebellar and supratentorial brain atrophy. Transmission electron microscopy analysis of peripheral mononuclear cells showed reduction of intracytoplasmatic inclusions with treatment. SRT with miglustat of patients with jGM2g failed to ameliorate progressive neurological deterioration, but apparently no worsening of some areas of cognitive function tested and brain MRI lesions was noted over 24 months of treatment. The results must be interpreted with care owing to the small sample of patients and the lack of a control-arm.",
keywords = "Juvenile GM2 gangliosidosis, Miglustat, Sandhoff disease, Substrate reduction therapy, Tay-Sachs disease",
author = "Maegawa, {Gustavo H B} and Banwell, {Brenda L.} and Susan Blaser and Geoffrey Sorge and Maggie Toplak and Cameron Ackerley and Cynthia Hawkins and Jason Hayes and Clarke, {Joe T R}",
year = "2009",
month = "10",
doi = "10.1016/j.ymgme.2009.06.005",
language = "English (US)",
volume = "98",
pages = "215--224",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "1-2",

}

TY - JOUR

T1 - Substrate reduction therapy in juvenile GM2 gangliosidosis

AU - Maegawa, Gustavo H B

AU - Banwell, Brenda L.

AU - Blaser, Susan

AU - Sorge, Geoffrey

AU - Toplak, Maggie

AU - Ackerley, Cameron

AU - Hawkins, Cynthia

AU - Hayes, Jason

AU - Clarke, Joe T R

PY - 2009/10

Y1 - 2009/10

N2 - Substrate reduction therapy (SRT) is considered to be a potential therapeutic option for juvenile GM2 gangliosidosis (jGM2g). We evaluated the efficacy of SRT in jGM2g, assessing neurological, neuropsychological and brain magnetic resonance imaging (MRI) outcomes over a 24-month period of treatment. In an open-label and single-center study, five jGM2g patients (mean age 14.6 ± 4.5 years) received oral miglustat at doses of 100-200 mg t.i.d. adjusted to body surface area. Patients underwent general and neurological examinations, neuropsychological, electrophysiological, and brain MRI studies. All patients showed neurological deterioration over the period of the study, with particularly notable worsening of gait, speech and coordination. One patient experienced acute psychosis, and another showed worsening of pre-existing epilepsy. Some neuropsychological tests showed no evidence of deterioration in the three patients with high enough cognitive functioning for reliable assessment. Profound cognitive impairment in two children precluded neuropsychological evaluation. In four patients, evaluation of brain MRI showed no changes in white matter signal abnormalities and cerebellar atrophy noted at baseline, while one patient showed progression of cerebellar and supratentorial brain atrophy. Transmission electron microscopy analysis of peripheral mononuclear cells showed reduction of intracytoplasmatic inclusions with treatment. SRT with miglustat of patients with jGM2g failed to ameliorate progressive neurological deterioration, but apparently no worsening of some areas of cognitive function tested and brain MRI lesions was noted over 24 months of treatment. The results must be interpreted with care owing to the small sample of patients and the lack of a control-arm.

AB - Substrate reduction therapy (SRT) is considered to be a potential therapeutic option for juvenile GM2 gangliosidosis (jGM2g). We evaluated the efficacy of SRT in jGM2g, assessing neurological, neuropsychological and brain magnetic resonance imaging (MRI) outcomes over a 24-month period of treatment. In an open-label and single-center study, five jGM2g patients (mean age 14.6 ± 4.5 years) received oral miglustat at doses of 100-200 mg t.i.d. adjusted to body surface area. Patients underwent general and neurological examinations, neuropsychological, electrophysiological, and brain MRI studies. All patients showed neurological deterioration over the period of the study, with particularly notable worsening of gait, speech and coordination. One patient experienced acute psychosis, and another showed worsening of pre-existing epilepsy. Some neuropsychological tests showed no evidence of deterioration in the three patients with high enough cognitive functioning for reliable assessment. Profound cognitive impairment in two children precluded neuropsychological evaluation. In four patients, evaluation of brain MRI showed no changes in white matter signal abnormalities and cerebellar atrophy noted at baseline, while one patient showed progression of cerebellar and supratentorial brain atrophy. Transmission electron microscopy analysis of peripheral mononuclear cells showed reduction of intracytoplasmatic inclusions with treatment. SRT with miglustat of patients with jGM2g failed to ameliorate progressive neurological deterioration, but apparently no worsening of some areas of cognitive function tested and brain MRI lesions was noted over 24 months of treatment. The results must be interpreted with care owing to the small sample of patients and the lack of a control-arm.

KW - Juvenile GM2 gangliosidosis

KW - Miglustat

KW - Sandhoff disease

KW - Substrate reduction therapy

KW - Tay-Sachs disease

UR - http://www.scopus.com/inward/record.url?scp=67651232532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651232532&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2009.06.005

DO - 10.1016/j.ymgme.2009.06.005

M3 - Article

C2 - 19595619

AN - SCOPUS:67651232532

VL - 98

SP - 215

EP - 224

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 1-2

ER -